Can a new pill help manage weight? a First-in-Human trial begins
NCT ID NCT07089823
First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time
Summary
This early-stage trial is testing an experimental drug called YP05002 in healthy adults aged 18 to 65. The goal is to see if the drug is safe and how the body processes it. Participants receive either the drug or a placebo, and researchers monitor for side effects and measure drug levels in the blood. This is a first step toward understanding whether YP05002 could one day help with weight management.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- an experimental drug called YP05002
- What this could lead to
- If safe and effective, YP05002 could offer a new option for weight management.
- What could go wrong
- This is an early phase 1 trial focused on safety, not weight loss. The drug may not work or could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
79 people
The number who actually took part.
- Started
-
Aug 2025
- Finished
-
Mar 2026
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures. 2. Healthy male and female participants aged 18-65 years (both inclusive).No restrictions on race. 3. In good health as determined by the Investigator, with no clinically significant findings from medical/psychiatric history, physical examination, 12-lead ECG, vital signs measurements, clinical laboratory evaluations. Exclusion Criteria: 1. Have evidence of any clinically significant active or chronic disease. 2. Histories of using drug that affect drug absorption, distribution, metabolism, or excretion within 14 days or within 5-half-life prior to the first dose (whichever is longer); gastrointestinal disorders with impaired gastric emptying; or prolonged use of medications that directly modulate gastrointestinal motility. 3. Had clinically relevant acute or chronic medical conditions or diseases that would pose a risk to participant's safety or interfere with the study assessments, as determined by the Investigator. 4. Any malignancy (except basal cell carcinoma and squamous cell carcinoma of the skin) in the previous 5 years. 5. Diagnosis of any type of pancreatitis.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Weight management are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Nucleus Network Melbourne Clinic
Melbourne, Victoria, 3004, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Do GLP-1 Weight-Loss drugs change how teens eat and feel?
- Can one workout change your gut bacteria?
- Portion control tools and an app put to the test for weight management
- Can a daily probiotic boost metabolic health and body confidence?
- A new program aims to ease the 'Lost in Transition' struggle for cancer survivors
- Cooking classes and tailored groceries could help teens manage weight